Initiating the commercialization of genetically modified staple crops in China: domestic biotechnological advancements, regulatory milestones, and governance frameworks

启动中国转基因主粮作物商业化:国内生物技术进展、监管里程碑和治理框架

阅读:1

Abstract

Historically, China's approach to genetically modified (GM) staple crops has been cautious. However, in 2021, China launched its first pilot program for the commercial cultivation of GM food crops and subsequently expanded their cultivation. Previously, the only GM plants cultivated in China were insect-resistant cotton and virus-resistant papaya. The regulatory and policy shifts, from initial research and cautious development to accelerated commercialization, led to significant changes in China's safety-related regulatory framework for genetically modified organism (GMOs). Here, China's progress in GMO research and commercialization over the past three decades is comprehensively analyzed. This review traces the evolution of core regulations governing GMO safety, summarizes the Chinese model of GMO safety governance, and highlights the remaining challenges as commercialization progresses. The goal was to present the international community with a GMO safety governance model reflecting China's characteristics and practices, offering a Chinese solution to balancing GMO commercial adoption with ecological preservation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。